With $22M B round, Numab to build out multispecific mAb pipeline

Following a run of partnerships with Asian companies, Numab has closed a series B round to enable the Swiss biotech to focus on expanding its pipeline of multispecific mAbs.

Numab Therapeutics AG announced Monday that it topped off the series B with an additional CHF7 million ($7.1 million), bringing the round to CHF22 million. New investors included Mitsubishi UFJ Capital, corporate partner Eisai Co. Ltd. (Tokyo:4523) and Daniel Vasella, a Numab board member and former chairman and CEO of Novartis AG (NYSE:NVS; SIX:NOVN)...